Rezolute (RZLT) Registration Filing summary

Company overview and business model

• Focuses on developing transformative therapies for rare diseases with significant unmet needs, primarily targeting hypoglycemia due to hyperinsulinism (HI) and diabetic macular edema (DME).

• Lead asset, ersodetug, is a monoclonal antibody for HI, with ongoing Phase 3 trials for congenital and tumor-related HI.

• RZ402, an oral plasma kallikrein inhibitor, is in development for DME, having completed a successful Phase 2 trial.

Financial performance and metrics

• Gross proceeds from the private placement were approximately $4.2 million, with shares sold at $3.25 each.

• As of July 14, 2025, 86,995,985 shares of common stock were outstanding.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; all proceeds from the private placement have already been received by the company.